{"nctId":"NCT00947115","briefTitle":"Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects","startDateStruct":{"date":"2009-09-22","type":"ACTUAL"},"conditions":["Infections, Papillomavirus"],"count":525,"armGroups":[{"label":"Cervarix 15-25 years group","type":"EXPERIMENTAL","interventionNames":["Procedure: Blood sampling","Procedure: Cervico-vaginal secretion (CVS) samples"]},{"label":"Cervarix 26-45 years group","type":"EXPERIMENTAL","interventionNames":["Procedure: Blood sampling","Procedure: Cervico-vaginal secretion (CVS) samples"]},{"label":"Cervarix 46-55 years group","type":"EXPERIMENTAL","interventionNames":["Procedure: Blood sampling","Procedure: Cervico-vaginal secretion (CVS) samples"]}],"interventions":[{"name":"Blood sampling","otherNames":[]},{"name":"Cervico-vaginal secretion (CVS) samples","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believed that they could and would comply with the requirements of the protocol.\n* A female who had been enrolled in NCT00196937 study and received three doses of HPV-16/18 vaccine.\n* Written informed consent obtained from the subject.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.\n* Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs occurring less than three months prior to blood sampling.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n* Administration of immunoglobulins and/or any blood products within the three months preceding blood sampling.\n* Administration or planned administration of any HPV vaccine, other than the three doses of HPV-16/18 vaccine administered in NCT00196937 study.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Anti-Human Papillomavirus (Anti-HPV)-16/18 Antibody Titers in Serum at Years 5, 6 and 7","description":"Anti-HPV-16/18 antibody titers are presented as Geometric Mean Titers (GMTs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).\n\nThe immune response of the HPV-16/18 vaccine (as determined by anti-HPV-16/18 antibodies assessed by ELISA) in the HPV-060 study population was compared with the immune response obtained in study HPV-001 and its long-term follow-up studies HPV-007/HPV-023 at equivalent timepoints and with the immune response obtained after natural infection in subjects from study HPV-008.\n\nThe immune response data for the efficacy studies HPV-001/HPV-007/HPV-023 can be found under the NCT record NCT00518336. The immune response data for the HPV-008 study can be found under the NCT record NCT00122681.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1495.7","spread":null},{"groupId":"OG001","value":"518.7","spread":null},{"groupId":"OG002","value":"282.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1344.6","spread":null},{"groupId":"OG001","value":"526.0","spread":null},{"groupId":"OG002","value":"277.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1014.0","spread":null},{"groupId":"OG001","value":"369.5","spread":null},{"groupId":"OG002","value":"201.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"440.4","spread":null},{"groupId":"OG001","value":"168.8","spread":null},{"groupId":"OG002","value":"104.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"438.2","spread":null},{"groupId":"OG001","value":"167.5","spread":null},{"groupId":"OG002","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307.8","spread":null},{"groupId":"OG001","value":"119.8","spread":null},{"groupId":"OG002","value":"81.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-HPV-16/18 Antibody Titers in Serum at Years 8, 9 and 10","description":"Anti-HPV-16/18 antibody titers are presented as Geometric Mean Titers (GMTs) and expressed in EL.U/mL.\n\nThe immune response of the HPV-16/18 vaccine (as determined by anti-HPV-16/18 antibodies assessed by ELISA) in the HPV-060 study population was compared with the immune response obtained in study HPV-001 and its long-term follow-up studies HPV-007/HPV-023 at equivalent timepoints and with the immune response obtained after natural infection in subjects from study HPV-008.\n\nThe immune response data for the efficacy studies HPV-001/HPV-007/HPV-023 can be found under the NCT number NCT00518336. The immune response data for the HPV-008 study can be found under the NCT number NCT00122681.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1123.3","spread":null},{"groupId":"OG001","value":"392.1","spread":null},{"groupId":"OG002","value":"189.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"980.9","spread":null},{"groupId":"OG001","value":"366.5","spread":null},{"groupId":"OG002","value":"180.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"965.4","spread":null},{"groupId":"OG001","value":"334.4","spread":null},{"groupId":"OG002","value":"157.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"375.1","spread":null},{"groupId":"OG001","value":"134.1","spread":null},{"groupId":"OG002","value":"82.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"327.4","spread":null},{"groupId":"OG001","value":"122.5","spread":null},{"groupId":"OG002","value":"75.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"321.1","spread":null},{"groupId":"OG001","value":"115.4","spread":null},{"groupId":"OG002","value":"69.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies at Years 5, 6 and 7","description":"Seroconversion was defined as the appearance of anti-HPV-16 and anti- HPV-18 antibodies \\[i.e. antibody titer greater than or equal to (≥) the cut-off value\\] in the serum of subjects seronegative before vaccination in the primary study HPV-014 (NCT00196937). Cut-off values were 8 EL.U/mL for anti-HPV-16 antibody titers and 7 EL.U/mL for anti-HPV-18 antibody titers.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"127","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"135","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies at Years 8, 9 and 10","description":"Seroconversion was defined as the appearance of anti-HPV-16 and anti-HPV-18 antibodies (i.e. antibody titer ≥ the cut-off value) in the serum of subjects seronegative before vaccination in the primary study HPV-014 (NCT00196937). Cut-off values were 19 EL.U/mL for anti-HPV-16 antibody titers and 18 EL.U/mL for anti-HPV-18 antibody titers.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"132","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS) Samples at Years 5 and 6 in a Subset of Subjects","description":"Anti-HPV-16/18 titers in CVS samples are presented as GMTs and expressed in EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null},{"groupId":"OG001","value":"47.2","spread":null},{"groupId":"OG002","value":"56.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":null},{"groupId":"OG001","value":"24.6","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":null},{"groupId":"OG001","value":"43.8","spread":null},{"groupId":"OG002","value":"37.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"19.9","spread":null},{"groupId":"OG002","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HPV-16/18 Secretion Antibody Titers in CVS Samples at Years 7, 8, 9 and 10 in a Subset of Subjects","description":"Anti-HPV-16/18 titers in CVS samples are presented as GMTs and expressed in EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"42.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","spread":null},{"groupId":"OG001","value":"17.5","spread":null},{"groupId":"OG002","value":"49.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null},{"groupId":"OG001","value":"43.9","spread":null},{"groupId":"OG002","value":"54.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"26.2","spread":null},{"groupId":"OG002","value":"31.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null},{"groupId":"OG001","value":"42.6","spread":null},{"groupId":"OG002","value":"62.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"23.9","spread":null},{"groupId":"OG002","value":"50.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"34.3","spread":null},{"groupId":"OG002","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"22.7","spread":null},{"groupId":"OG002","value":"45.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS Samples at Years 5 and 6 in a Subset of Subjects","description":"IgG antibody titers in CVS samples are presented as GMTs and expressed in microgram per milliliter (µg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"577.8","spread":null},{"groupId":"OG001","value":"550.5","spread":null},{"groupId":"OG002","value":"990.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"546.5","spread":null},{"groupId":"OG001","value":"499.8","spread":null},{"groupId":"OG002","value":"1012.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Total IgG Secretion Antibody Titers in CVS Samples at Years 7, 8, 9, and 10 in a Subset of Subjects","description":"Total IgG antibody titers in CVS samples are presented as GMTs and expressed in microgram per milliliter (µg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"517.5","spread":null},{"groupId":"OG001","value":"372.2","spread":null},{"groupId":"OG002","value":"1263.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"304.8","spread":null},{"groupId":"OG001","value":"457.2","spread":null},{"groupId":"OG002","value":"928.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"435.1","spread":null},{"groupId":"OG001","value":"460.4","spread":null},{"groupId":"OG002","value":"925.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"315.3","spread":null},{"groupId":"OG001","value":"373.5","spread":null},{"groupId":"OG002","value":"622.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Total IgG Antibody Titers in Serum at Years 5, 6 and 7 Based on the ATP Cohort for Immunogenicity","description":"Total IgG antibody titers are presented as GMTs and expressed in µg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19481.8","spread":null},{"groupId":"OG001","value":"18388.2","spread":null},{"groupId":"OG002","value":"17657.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13376.5","spread":null},{"groupId":"OG001","value":"12262.7","spread":null},{"groupId":"OG002","value":"12040.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13957.2","spread":null},{"groupId":"OG001","value":"13179.4","spread":null},{"groupId":"OG002","value":"12992.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Total IgG Antibody Titers in Serum at Years 8, 9 and 10 Based on the ATP Cohort for Immunogenicity","description":"Total IgG antibody titers are presented as GMTs and expressed in µg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11059.5","spread":null},{"groupId":"OG001","value":"10656.3","spread":null},{"groupId":"OG002","value":"10605.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11212.2","spread":null},{"groupId":"OG001","value":"10693.8","spread":null},{"groupId":"OG002","value":"10427.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11071.3","spread":null},{"groupId":"OG001","value":"10650.8","spread":null},{"groupId":"OG002","value":"10535.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total IgG Antibody Titers in Serum at Years 5, 6 and 7 Based on the TVC","description":"Total IgG antibody titers are presented as GMTs and expressed in µg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19453.0","spread":null},{"groupId":"OG001","value":"18092.4","spread":null},{"groupId":"OG002","value":"17885.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13318.5","spread":null},{"groupId":"OG001","value":"12173.1","spread":null},{"groupId":"OG002","value":"12040.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13957.2","spread":null},{"groupId":"OG001","value":"13059.5","spread":null},{"groupId":"OG002","value":"13052.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Total IgG Antibody Titers in Serum at Years 8, 9 and 10 Based on the TVC","description":"Total IgG antibody titers are presented as GMTs and expressed in µg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11084.4","spread":null},{"groupId":"OG001","value":"10602.4","spread":null},{"groupId":"OG002","value":"10725.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11212.2","spread":null},{"groupId":"OG001","value":"10693.8","spread":null},{"groupId":"OG002","value":"10427.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11043.6","spread":null},{"groupId":"OG001","value":"10511.3","spread":null},{"groupId":"OG002","value":"10484.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Fatal or Vaccine-related SAEs (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication) From Year 4 in Primary Study HPV-014 (NCT00196937) to Year 5 in the Present Study","description":"SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject, or may have evolved into one of the outcomes listed above. Related SAE = SAE assessed by the investigator as causally related to the study vaccine administered in study HPV-014 (NCT00196937).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Fatal or Vaccine-related SAEs (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication) From Year 5 to Year 6","description":"SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject, or may have evolved into one of the outcomes listed above. Related SAE = SAE assessed by the investigator as causally related to the study vaccine administered in study HPV-014 (NCT00196937).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Fatal or Vaccine-related SAEs (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication) From Year 6 to Year 7","description":"SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject, or may have evolved into one of the outcomes listed above. Related SAE = SAE assessed by the investigator as causally related to the study vaccine administered in study HPV-014 (NCT00196937).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Fatal or Vaccine-related SAEs (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication) From Year 7 to Year 8","description":"SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject, or may have evolved into one of the outcomes listed above. Related SAE = SAE assessed by the investigator as causally related to the study vaccine administered in study HPV-014 (NCT00196937).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Fatal or Vaccine-related SAEs (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication) From Year 8 to Year 9","description":"SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject, or may have evolved into one of the outcomes listed above. Related SAE = SAE assessed by the investigator as causally related to the study vaccine administered in study HPV-014 (NCT00196937).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Fatal or Vaccine-related SAEs (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication) From Year 9 to Year 10","description":"SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject, or may have evolved into one of the outcomes listed above. Related SAE = SAE assessed by the investigator as causally related to the study vaccine administered in study HPV-014 (NCT00196937).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Fatal or Vaccine-related SAEs (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication) From Year 0 to Year 10","description":"SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject. Related SAE = SAE assessed by the investigator as causally related to the study vaccine administered in study HPV-014 (NCT00196937).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":159},"commonTop":[]}}}